About Roche Pars
Roche was founded in 1896 Basel, Switzerland. Investing an amount of CHF 11 Billion in the Research and Development fields, innovating more than 30 medicines enlisted in the WHO Essential Medicine List (see remark) during 120 years of dedication to healthcare, has titled Roche as the world’s largest biotechnology company providing ground-breaking services and innovation in the fields of diagnostics, personalized healthcare, diabetes management, in vitro diagnostics, and oncology. Roche operates in over 100 counties across the globe and is home to 94,000 staff.
Roche Pars, the affiliate of this world leading fully integrated personalized healthcare company in the Islamic Republic of Iran, officially began its operations in the country in the year 2013 and established its head offices in Tehran in 2013. Roche Pars’s operations are chiefly focused on pharma, diagnostics, and diabetes.
Over the course of its 25 year journey in the Islamic Republic of Iran, Roche Pars’s various scientific and fundamental collaborations with the country’s leading experts has created a credible name and reputation for the company among the country’s physician community, related organizations, and local competition. Providing free education to medical associations, raising public awareness in the field of hematology, oncology, and neurological diseases, and collaborating with NGOs are amongst Roche Pars’ activities in Iran. With an aim to enable and further enhance (licensed) local production of pharmaceuticals, Roche Pars strives to facilitate local knowledge-intensive companies through know-how and technology transfer.
Roche Pars has taken significant steps in the country’s pharmaceutical industry during the past two decades, the most influential of which would be a tripartite Memorandum of Understanding in 2002, marking a collaboration for the local production of Cellcept, along with the local production of Roaccutane soft capsules. It is interesting to note that it was the first time that this particular medicine and its formula was being produced in a site outside of its original company in Germany.